21.70
+4.83%
Close of 9 Nov 2026, in NOK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Arcticzymes Technologies A
Its shares trade on Oslo Børs under the ticker AZT.OL. It has been listed since 4 November 2005. In the fiscal year to 31 December 2025, it reported revenue of NOK 112.6m and net income of NOK 9.9m. At that date it held total assets of NOK 361.4m and shareholders' equity of NOK 338.5m.
ArcticZymes Technologies ASA is a holding company, which engages in the development, manufacture, and marketing of immunomodulatory products and cold adapted marine enzymes. The company is headquartered in Tromso, Troms. The company went IPO on 2005-11-04. The firm focuses on new solutions within molecular research, in vitro diagnostics and therapeutics. Arcticzymes Technologies ASA invests in BetaGlucans, which develops immunomodulating beta-glucan products, serving several different market segments including wound care, animal and consumer health and adjuvants.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 4 Nov 2005
- Employees
- 38
- Website
- arcticzymes.com ↗
Leadership
Pay as last reported
- Mr. Michael AkohChief Executive Officer
- Mr. Borge SorvollChief Financial OfficerNOK 1.9m
- Dr. Darren EllisChief Scientific Officer
- Dr. Olav LanesVice President - Applications, Research and Development, since 2011NOK 1.2m
- Dr. Marit Sjo LorentzenOperations Director, Director - Employee Elected, since 2020NOK 1.2m
- Mr. Volker WedershovenDirectorNOK 270,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Arcticzymes Technologies ASA is known for its strong capabilities in developing innovative technologies, particularly in the field of enzymes. Their cutting-edge solutions have gained recognition and established them as a leader in the industry.
- The company offers a wide range of high-quality products, including enzymes, nucleotides, and other molecular biology tools. This diverse portfolio allows Arcticzymes to cater to varied customer needs and maintain a competitive edge.
- Arcticzymes has a strong IP portfolio, which includes patents and proprietary technology. This provides them with a significant advantage in terms of protecting their innovations and maintaining exclusivity in the market.
Weaknesses
- Arcticzymes primarily operates within niche markets, limiting their customer base and potential for growth. Dependence on a few industries might expose the company to market fluctuations and economic downturns in those sectors.
- The company's operations are concentrated in specific regions, which can pose challenges in terms of market expansion and diversification. Over-reliance on specific geographic markets may limit their global reach and impact.
Opportunities
- The biotechnology industry is experiencing rapid growth, presenting opportunities for Arcticzymes Technologies ASA to expand its market presence. The increasing demand for innovative enzyme solutions in various sectors provides a favorable environment for business growth.
- Collaborating with other key players in the industry, such as research institutions, pharmaceutical companies, or manufacturers, can help Arcticzymes gain access to new markets, enhance product development, and create mutually beneficial business opportunities.
Threats
- The biotechnology sector is highly competitive, with numerous companies vying for market share. Arcticzymes faces the risk of new entrants, potential substitutes, and established competitors offering similar enzyme solutions, which could impact their market position and profitability.
- The biotechnology industry is subject to extensive regulations and legal requirements, especially regarding patents, intellectual property rights, and product safety. Non-compliance or changes in regulations could disrupt business operations and result in increased costs and restrictions.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.